Showing 1 - 9 of 9
Persistent link: https://www.econbiz.de/10001203205
Persistent link: https://www.econbiz.de/10010233927
Persistent link: https://www.econbiz.de/10010378905
Persistent link: https://www.econbiz.de/10003684914
Persistent link: https://www.econbiz.de/10011317950
An instrumental variable econometric model is specified to investigate how changes in a country’s patent protection for pharmaceutical innovations are related to patent awards from the U.S. Patent and Trademark Office to the country’s applicants. We use a new measure of patent protection for...
Persistent link: https://www.econbiz.de/10009645439
Building on the seminal work of Ginarte and Park (1997. Research Policy. 26, 283–301), we develop an index of property rights in pharmaceutical inventions, the Pharmaceutical Intellectual Property Protection (PIPP) Index, for 154 countries spanning 1960 to 2005. It incorporates five types of...
Persistent link: https://www.econbiz.de/10011116604
The World Health Organization estimated that in 1999 roughly one-third of the world's population lacked access to essential medicines that would have saved or improved their lives. Our analysis focuses on how pharmaceutical product patents restrict access to essential medicines in developing...
Persistent link: https://www.econbiz.de/10015383964
We use dynamic panel data regressions to investigate whether the strength of a country’s patent protection for pharmaceuticals is associated with more pharmaceutical patenting by its residents and corporations in the United States. Using the Pharmaceutical Intellectual Property Protection...
Persistent link: https://www.econbiz.de/10011162942